01—Abstract
Summary
Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 5, 2026.
Of the 118,474,300 shares of common stock outstanding as of the record date, 104,138,244 shares were represented at the meeting. The filing states that stockholders considered three proposals, each described in the Company's definitive proxy statement filed with the SEC on March 23, 2026. Stockholders elected two Class I directors, Bernadette Connaughton and Matthew L.
Posard, to three-year terms expiring at the 2029 Annual Meeting. Each received affirmative votes from more than a majority of outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the Company's named executive officers, with 84,682,518 votes for, 9,311,426 against, 255,081 abstentions and 9,889,219 broker non-votes.
Stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 103,197,579 votes for, 849,433 against and 91,232 abstentions. The filing reports no broker non-votes for this proposal.
02—Key points
Key Highlights
- Annual Meeting of Stockholders held May 5, 2026; 104,138,244 of 118,474,300 outstanding shares as of the record date were represented.
- Bernadette Connaughton elected as a Class I director with 89,053,734 votes for and 5,068,160 against, for a term expiring at the 2029 Annual Meeting.
- Matthew L. Posard elected as a Class I director with 82,739,433 votes for and 10,236,878 against, for a term expiring at the 2029 Annual Meeting.
- Advisory say-on-pay proposal approved: 84,682,518 votes for, 9,311,426 against, 255,081 abstentions, and 9,889,219 broker non-votes.
- Ernst & Young LLP ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 103,197,579 votes for and 849,433 against.
- The filing references the definitive proxy statement filed with the SEC on March 23, 2026, which describes each proposal in more detail.
03—Questions
Frequently Asked Questions
Who was elected to the Board at the May 5, 2026 annual meeting?
Bernadette Connaughton and Matthew L. Posard were elected as Class I directors. Each will serve a three-year term expiring at the 2029 Annual Meeting of Stockholders or until a successor is duly elected and qualified.
Did stockholders approve the executive compensation proposal?
Yes. The advisory vote on named executive officer compensation was approved, with 84,682,518 votes for and 9,311,426 votes against, along with 255,081 abstentions and 9,889,219 broker non-votes.
Which independent auditor did stockholders ratify?
Stockholders ratified Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 103,197,579 votes for, 849,433 against and 91,232 abstentions.
How many shares participated in the meeting?
104,138,244 shares were represented at the meeting, out of 118,474,300 shares of common stock outstanding as of the record date.
04—Continue